Monte Rosa Therapeutics

Q2 FY2026 EarningsQ2 FY2026 results missed consensus estimates on the top and bottom lines. Collaboration revenue of $9.0M fell significantly short of the $12.9M expectation (-30.36%), while Net Loss of $43.4M was wider than the $38.5M consensus. Despite the financial miss, the company maintains a robust cash position of $626M (runway into 2029) and achieved key clinical milestones, including completing GFORCE-1 enrollment and Novartis-led Phase 2 activation for MRT-6160.